Adult acute lymphoblastic leukemia

Elias J. Jabbour; Stefan Faderl; Hagop M. Kantarjian

doi:10.4065/80.11.1517

Adult acute lymphoblastic leukemia

Elias J. Jabbour, Stefan Faderl, Hagop M. Kantarjian

Leukemia

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Abstract

Much progress has been made In understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated Into the recognition of several subgroups of ALL and the Institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies In children with ALL das resulted in similar complete remission rates In adults. Prognosis has improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival In adults Is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success In adult ALL.

Original language	English (US)
Pages (from-to)	1517-1527
Number of pages	11
Journal	Mayo Clinic Proceedings
Volume	80
Issue number	11
DOIs	https://doi.org/10.4065/80.11.1517
State	Published - Nov 2005

ASJC Scopus subject areas

General Medicine

Access to Document

10.4065/80.11.1517

Cite this

@article{ba1e0a8868d24ca89c51ed2013471af5,

title = "Adult acute lymphoblastic leukemia",

abstract = "Much progress has been made In understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated Into the recognition of several subgroups of ALL and the Institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies In children with ALL das resulted in similar complete remission rates In adults. Prognosis has improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival In adults Is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success In adult ALL.",

author = "Jabbour, {Elias J.} and Stefan Faderl and Kantarjian, {Hagop M.}",

year = "2005",

month = nov,

doi = "10.4065/80.11.1517",

language = "English (US)",

volume = "80",

pages = "1517--1527",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "11",

}

TY - JOUR

T1 - Adult acute lymphoblastic leukemia

AU - Jabbour, Elias J.

AU - Faderl, Stefan

AU - Kantarjian, Hagop M.

PY - 2005/11

Y1 - 2005/11

N2 - Much progress has been made In understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated Into the recognition of several subgroups of ALL and the Institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies In children with ALL das resulted in similar complete remission rates In adults. Prognosis has improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival In adults Is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success In adult ALL.

AB - Much progress has been made In understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated Into the recognition of several subgroups of ALL and the Institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies In children with ALL das resulted in similar complete remission rates In adults. Prognosis has improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival In adults Is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success In adult ALL.

UR - http://www.scopus.com/inward/record.url?scp=27644551821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644551821&partnerID=8YFLogxK

U2 - 10.4065/80.11.1517

DO - 10.4065/80.11.1517

M3 - Article

C2 - 16295033

AN - SCOPUS:27644551821

SN - 0025-6196

VL - 80

SP - 1517

EP - 1527

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

IS - 11

ER -

Adult acute lymphoblastic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this